Press Releases

May 29, 2020

Valneva Confirms Repurchase of Preferred Shares in Accordance with the Company’s Articles

May 27, 2020

Valneva Announces the Availability of Documentation for its Closed-Door Combined General Meeting

May 7, 2020

Valneva Reports Q1 Results and Updates 2020 Guidance Following Major Lyme Partnering Deal

May 5, 2020

Valneva to Partner with Instituto Butantan on Single-Shot Chikungunya Vaccine for Low- and Middle-Income Countries

April 30, 2020

Valneva and Pfizer Announce Collaboration to Co-Develop and Commercialize Lyme Disease Vaccine, VLA15

April 22, 2020

Valneva and Dynavax Announce Collaboration to Advance Vaccine Development for COVID-19

March 31, 2020

Valneva Announces the Publication of its 2019 Universal Registration Document

March 25, 2020

Valneva Reports Positive End-of-Phase 2 Chikungunya Meeting with the U.S. FDA; Sets Stage for Phase 3 Study

March 24, 2020

Valneva Provides Business Update on COVID-19 Situation

March 8, 2020

Valneva Announces FDA Approval of IXIARO® Shelf Life Extension to 36 Months; New US Military RFP Issued

1
2
3
…
33